儿科产品是亚宝药业的重点品类，业绩会中，任蓬勃向财联社记者介绍，今年1-9月，公司儿科类产品实现营业收入6.76亿，同比增长1.23%，占总营收的31.85%。细分来看，“今年前三季度，意芽健脾凝胶实现销售收入同比增长24%；儿童清咽解热口服液实现销售收入同比增长64%；丁桂儿脐贴实现营收3.56亿元，同比下降8%。”公司总经理任伟表示。Yabao Pharmaceutical Group stated at the earnings conference that in the first three quarters of this year, the revenue of pediatric products increased compared to the same period last year. The company secretary expressed that while the revenue of metoprolol tartrate injection declined, the sales volume increased slightly, and it is predicted that the 'income decline in this category will continue to narrow within the year'. Yabao Pharmaceutical Group also provided explanations on the progress of the company's pipeline research and development, share buybacks, and other situations.
Caixin News Agency, November 12th (Reporter He Fan) In today's 2024 third quarter earnings conference, Yabao Pharmaceutical Group (600351.SH) company secretary Ren Pengbo stated that in the first three quarters of this year, the revenue of pediatric products increased compared to the same period last year. While the revenue of metoprolol tartrate injection declined, sales volume increased slightly. It is expected that the 'income decline in this category will continue to narrow within the year'.
In addition, Yabao Pharmaceutical Group also provided explanations on the progress of the company's pipeline research and development and share buybacks.
Pediatric products are a key product category for Yabao Pharmaceutical Group. During the earnings conference, Ren Pengbo introduced to the Caixin News Agency reporters that from January to September this year, the company's pediatric products achieved revenue of 0.676 billion, a year-on-year increase of 1.23%, accounting for 31.85% of total revenue. In detail, 'In the first three quarters of this year, Yiyajianpi Gel achieved a 24% year-on-year growth in sales revenue; Children's throat-clearing and antipyretic oral liquid achieved a 64% year-on-year growth in sales revenue; Dinggui Er Navel Patch achieved revenue of 0.356 billion yuan, a year-on-year decrease of 8%.' the company's general manager Ren Wei said.
Previously, due to the impact of centralized procurement on the prescription drug metoprolol tartrate injection, sales of Yabao Pharmaceutical Group declined year-on-year in the first half of the year. Regarding the sales volume of this drug, Ren Pengbo informed Caixin News Agency reporters during this earnings conference, 'As of the end of June 2024, sales revenue of this product decreased by 48% year-on-year. As of the end of September 2024, this product achieved sales revenue of 0.139 billion, a year-on-year decrease of 47%, with a 20% year-on-year increase in sales volume. It is projected that the income decline will continue to narrow within the year.'
Investors are also paying close attention to the progress of new drug research and development at Yabao Pharmaceutical Group. Ren Wei revealed that SY-005 has completed Phase IIa clinical trials, and indications for treating stroke have been discovered during the development process, obtaining a patent authorization in the USA. The SY-009 project is in Phase II clinical trials; Chaihui Granules for treating depression are in Phase II clinical stage. Other products related to pediatric acute upper respiratory tract infections, pediatric cough variant asthma, childhood eczema, childhood pulmonary hot cough, etc., are all in the pre-clinical stage.
Regarding the previously announced repurchase matters, Ren Pengbo told Caixin News Agency reporters that as of October 31, 2024, the company has repurchased a total of 0.7717 million shares through centralized competitive trading. The repurchase is currently in progress and the latest developments will be announced in early December. On September 3, Yabao Pharmaceutical Group announced its intention to repurchase shares for cancellation with an amount ranging from 0.1 billion yuan to 0.15 billion yuan. The repurchase period shall not exceed 6 months from the date of approval at the shareholder meeting, and the repurchase price shall not exceed 6.95 yuan per share.
